Recombinant DNA Technology Market Research Report - Forecast to 2027

Recombinant DNA Technology Market Research Report: By Product (Medical, Non-Medical), Component (Expression System, Cloning Vector), Application (Food & Agriculture, Health & Disease), End-User (Biotechnology Companies, Pharmaceuticals) – Forecast to 2027

ID: MRFR/LS/4389-HCR | February 2021 | Region: Global | 100 pages         

Recombinant DNA Technology Market

Recombinant DNA Technology Market is expected to grow with a CAGR of 7.5% during the forecasted period.


By Product Medical Non-Medical
By Component Expression System Cloning Vector
By Application Food & Agriculture Health & Disease
By End-User Biotechnology Companies Pharmaceuticals

Key Players

  • Amgen Inc. (U.S.)
  • F. Hoffmann-La Roche Ltd (Switzerland)
  • Profacgen (U.S.)
  • Novartis AG (Switzerland)
  • Novo Nordisk A/S (Denmark
  • Genscript Biotech (U.S.)
  • Pfizer Inc. (U.S.)
  • Sanofi S.A. (France)
  • Eli Lilly and Company (U.S.)
  • Biogen Inc. (U.S.)


  • Gowing adoption of genetically modified biopesticides and crops
  • Increasing adoption of recombinant DNA technology
Speak to Analyst Request a Free Sample

Recombinant DNA Technology Market Overview

The Recombinant DNA Technology Market is predicted to grow market approximately 6.9% of CAGR for the forecast period of 2017 to 2023. The process that can alter and manipulate the DNA sequences is known as recombinant DNA technology. Recombinant DNA technology is used in genetically modified organisms and products with specific or superior abilities to survive in harsh conditions (G.M. crops), high productivity, and resistance to certain chemicals. 

Recombinant DNA technology has a huge application in many sectors. But the practical application of biotechnology in the specific field of genomics, development of pharmaceutical therapeutics, applied immunology, and diagnostic tools are the dominating factor for the Recombinant DNA Technology Market Growth. In the creation of recombinant DNA, many biological methods are involved by the research and development market. Moreover, the Recombinant DNA Technology treatment was developed to treat the leukemia disorder in conjugation between the University of Pennsylvania and the Novartis Corp. 

According to the Recombinant DNA Technology Market Outlook report, the global market is segmented into application, components, products, and end-users, fueling the Market Size for the research period. Along with that, the intended audiences such as Recombinant DNA Technology Test Kit Suppliers, Medical Research Laboratories, Research and Development (R&D) Companies, Recombinant DNA Technology Test Kit Manufacturers, and Academic Medical Institutes and Universities are playing an important role in increasing the demand of the global market for the forecast period. 

COVID-19 Impact Analysis

The ongoing COVID-19 pandemic has affected the Disposable Incontinence Products (DIPs) industry, potential opportunities, and market trends. During the pandemic, the global market lost its productivity and sales as many regions were in lockdown. But after a certain time, the government has permitted the essential items to be sold, which has brought little opportunities for the global market.

According to the Recombinant DNA Technology Market Forecast report, the global key players have adopted various methods and strategies to deliver the product to their customers.

Market Overview 

  • Major Drivers of the Market

The global Recombinant DNA Technology Market is driving its growth due to major factors such as the growing adoption of genetically modified biopesticides and crops and the increasing adoption of recombinant DNA technology in the industry biopharmaceuticals and the growing burden of chronic diseases. Moreover, the effective therapeutics demand for disease treatment is increasing due to a robust biopharmaceuticals pipeline and the growing requirements to enhance the recombinant protein production capacity.

The U.S. Food and Drug Administration (FDA) had approved more recombinant drugs as the pharmaceutical products synthesized through recombinant DNA technology. This approval has generated a secure feeling among the population, and the demand for recombinant DNA technology has been increased among the Recombinant DNA Technology Market industries.

  • Opportunities of the global market

I the North American and Western European regions, the genetic testing market grows larger, spreading its hands to many remote areas. 

Therefore, this can bring more opportunities for the service providers and companies to make the tests more affordable. Along with that, the global Recombinant DNA Technology Market is trying to enter the untapped regions to bring lucrative opportunities. 

  • Market Restraints

The global Recombinant DNA Technology Market might face major restraints due to the risk associated with gene therapy. Another major restraint can be the stringent regulation for the approval of the product in various regions.

Therefore, the global key players are focusing on these issues to get a better outcome. 

  • Market Growth challenges

The global Recombinant DNA Technology Market might face major challenges due to the potential risk occurring from the Gene therapy.

Moreover, the risks associated with the operations might bring challenges to the global Market. Hence, the key players are working on these factors to get the proper solution to these challenges. 

  • Cumulative growth Analysis

Presently, the Recombinant DNA Technology Market Size has improved compared to the previous years, which predicts that the global market has the higher Market Value for the forecast period. 

Moreover, various regions such as America, Europe, the Middle East, Africa, and the Asia Pacific have been accounted to generate the higher Market Value in the upcoming years.

Market Segment Overview

By Product: The Recombinant DNA Technology Market has been classified into non-medical, medical, and others based on the product segment. 

Further, the non-medical segment is sub-classified into specialty chemicals, biotech crops, and others. On the other hand, the medical segment is sub-classified into human proteins, therapeutic agents, and vaccines. 

  • By Components:

The global Recombinant DNA Technology Market has been divided into a cloning vector, expression system, and component segment. 

Further, the Market Outlook report has mentioned that the cloning vector segment is sub-divided into cosmid, plasmid, phage, Human Artificial Chromosome (HAC), Yeast Artificial Chromosome (YAC), and Bacterial Artificial Chromosome (BAC). On the other hand, the expression system segment is sub-divided into bacteria, mammalian, baculovirus or insect, yeast, and others.

  • By Applications:

The global Recombinant DNA Technology Market has been classified into health and disease, food and agriculture, environment, and others based on the application segment.

Among these, the health & disease segment is generating the highest Market Share in the forecast period due to the increasing chronic diseases and wide range of recombinant products presence for the treatment of human disease like vaccines, drugs, etc.

  • By End-users:

The end-user segment of the global Recombinant DNA Technology Market has been divided into pharmaceuticals, academic and government research institutes, biotechnology companies, and others.

The biotechnology and pharmaceuticals companies are generating the higher Market Share for the research period due to their drug development capabilities. 

Figure 1: - Global Recombinant DNA Technology Market Share, by Region

 Recombinant DNA Technology Market Share

Regional Analysis

The global Recombinant DNA Technology Market has been segmented into Europe, the Americas, the Middle East and Africa, and the Asia Pacific based on regional segments. 

Among all, the Americas Market has accounted for the higher major share for the research period due to the widespread applications of this technique in genetically modified crops' development, veterinary products' development, gene therapy, and the production of biopesticides' and biofuels' production. Hence, these factors are fueling the Market Growth during the forecast period. Moreover, the European region holds the second dominating marketing region that contributes the largest Market share in the assessment period due to the government's increasing investments and hospital facilities for quality healthcare facilities. Also, the market is growing with the low cost of sequencing, increasing collaborations and partnerships, and the increasing demands of the research laboratories for the NGS procedure. 

Competitive Landscape Analysis

The global Recombinant DNA Technology Market Trends with the collective efforts of the key players in various regions of the world. These key players are:

  • Amgen Inc. (U.S.), 

  • F. Hoffmann-La Roche Ltd (Switzerland), 

  • Profacgen (U.S.), 

  • Novartis AG (Switzerland), 

  • Novo Nordisk A/S (Denmark), 

  • Genscript Biotech (U.S.), 

  • Pfizer Inc. (U.S.), 

  • Sanofi S.A. (France), 

  • Eli Lilly and Company (U.S.), 

  • Biogen Inc. (U.S.), 

  • Biocon Limited (India), 

  • Boehringer Ingelheim (Germany), 

  • Merck & Co., Inc. (U.S.), 

  • Cibus (U.S.), 

  • GlaxoSmithKline plc (UK), 

  • New England Biolabs (U.S.), 

  • Horizon Discovery Group PLC (U.S.),

  • Monsanto Company (U.S.).

The above-mentioned key players have lucrative opportunities due to the large application of the Recombinant DNA Technology Market Trends.

Recent Developments

  • Clustered regularly interspaced short palindromic repeats (CRISPR) is a recent development that has brought solutions to the different species' problems. It has been developed to target the destruction of genes in human body cells.

Report Overview

The Recombinant DNA Technology Market Analysis report has involved both primary research and secondary research to get the insight data of the global market. In the primary research, primary quantitative surveys have been conducted to get the views of the wholesalers, manufacturers, and retailers. Moreover, the secondary research has gathered data about the competitive landscape, company development, market access scenario, epidemiology study, and market dynamics. Along with that, the data analysis has involved event analysis, market size estimation, company share analysis, market factor analysis, trade analysis, cost analysis, trend analysis, and others in measuring the performance of the global market.

Further, the Recombinant DNA Technology Market Analysis report has highlighted the recent developments over various world regions. Though, the report has mentioned some specific strategies and methods used by the key players to enhance the growth of the Market.

Segmental Table:

By Product:

  • non-medical, 

  • medical,

  • others

By Components: 

  • cloning vector, 

  • expression system, 

  • others

By Application:

  • health and disease, 

  • food and agriculture, 

  • environment, 

  • others

By End-users:

  • pharmaceuticals, 

  • academic and government research institutes, 

  • biotechnology companies, 

  • others

Speak to Analyst Ask for Customization

Frequently Asked Questions (FAQ) :

Recombinant DNA technology is a process that manipulates and alters the DNA sequences, resulting in a genetically modified organism.

Recombinant DNA Technology Market is expected to exhibit a strong 6.9% CAGR over the forecast period from 2017 to 2023.

Growing demand for recombinant DNA technology in therapeutic applications is a major driver for the market.

Americas hold the dominant share in the global Recombinant DNA Technology Market.

Leading players in the Recombinant DNA Technology Market include Novartis, Profacgen, and Amgen, among others.